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1. Introduction 
Cervical cancer (CC) is the second most common cancer among women worldwide. The 
highest incidence rates of CC are reported in Central and South America, East Africa, South 
and Southeast Asia and Melanesia. In 2005 there were, according to WHO projections, more 
than 500, 000 new cases and 274, 000 deaths from CC (WHO, 2007). This is due to the fact 
that the majority of women in the world do not have access to cervical screening, which can 
prevent up to 75% of CC cases (Ferlay et al., 2001). Predictions based on the passive growth 
of the population and the increase in life expectancy say that the expected number of CC 
cases in 2020 will increase by 40% worldwide, corresponding to 56% in developing countries 
and 11% in the developed parts of the world (Ferlay et al., 2001). 
The development of CC is preceded by a series of cellular abnormalities characterized by 
cytological and histological changes in cytoplasm maturation and nuclear irregularities. The 
disease starts as an atypical proliferation of epithelial cells that invade epithelial thickness 
and degenerate into more serious injuries that invade the stroma. The development of 
precancerous lesions of the cervix involves several events: exposure to a high-risk Human 
Papilloma Virus (HR-HPV) causes an initial infection of the squamous epithelium in the 
transformation zone, followed by morphological and biological alterations of the HPV 
infected cells (Walboomers et al., 1999).  
As the understanding of the natural history of the disease has improved, the classification of 
these lesions has received different names: PAP I to V, moderate dysplasia, severe 
carcinoma in situ, cervical intraepithelial neoplasia (CIN) I, II, III, low grade squamous 
intraepithelial lesions (LSIL) and high grade squamous intraepithelial lesions  (HSIL). 
Microscopically, the evolution of the lesion is characterized by the differentiation of 
epithelial cells that proliferate and invade the epithelial tissue. Progression is described in 
terms of increase in the degree of dysplasia (mild, moderate, severe) and carcinoma in situ 
(El-Ghobashy et al., 2005). Early lesions are now considered manifestations of HPV 
infection, which are characterized by the presence of nuclear changes and cell proliferation 
of the epithelium. These cellular abnormalities tend to regress spontaneously, but some of 
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these lesions, particularly those caused by highly oncogenic HPV (16, 18, 31, 33, 35, 45, 56, 
58) can modify the thickness of the epithelium and the disease (Nobbenhuis et al., 2001). 
LSIL and CIN II, have a diploid or polyploid DNA content, which correlates with their 
tendency to reverse. In contrast, CIN III is often aneuploid, has a greater degree of cellular 
atypia and is more likely to persist, or progress (Grubisi¢ et al., 2009). 
The causal role of HPV in CIN and CC has been firmly established biologically and 
epidemiologically (Walboomers et al., 1999). Current meta-analysis of the literature shows 
that the most common HPV types worldwide, in descending order of frequency, are HPV 
16, 18, 45, 31, 33, 52, 58 and 35. These are responsible for about 90% of all CC worldwide. 
The distribution is very similar to that of pre-invasive HSIL (Muñoz et al., 2004; Smith et al., 
2007). Since the main route of transmission of genital HPV is sexual, certain patterns of 
sexual behavior (age of onset of sexual activity, number of sexual partners and sexual 
behavior of the couple) are associated with an increased risk of infection with genital HPV. 
But persistent infection with HR-HPV is necessary for carcinogenesis, and cofactors such as 
multiparity, prolonged use of oral contraceptives, smoking and co-infection with HIV, 
enhance the progression of infection to cancer (Almonte et al., 2008).  
HPVs are species-specific and induce epithelial or fibroepithelial proliferations of benign 
skin and mucosa in humans and in several animal species. These viruses have a specific 
tropism for squamous epithelial cells and their production cycle only happens in these cells. 
HPV infection begins in the basal cells, which are mitotically active. After infection, the virus 
can lie dormant, replicate and produce infectious particles or become integrated into the 
cellular genome. Productive infection is divided into several stages depending on the state 
of differentiation of the epithelial cells. The full cycle that includes viral DNA synthesis, 
production of viral capsid proteins and assembly of virions, occurs selectively in terminally 
differentiated keratinocytes (Doorbar, 2006). The basal layer cells proliferate; despite 
containing HPV DNA, they appear to be very active in the expression of some viral proteins. 
Apparently, there are cellular factors that negatively regulate viral transcription in these 
cells.  
This regulation is released when the infected cells migrate upward from the epithelium in 
the granular layer, where they undergo differentiation until they can no longer divide. First, 
transcription of early and late viral genes is activated in these cells, viral proteins are then 
synthesized and viral particles are assembled in some superficial cells (Longworth et al., 
2004). Although most HPV infections are transient and subclinical, progression is strongly 
associated with HPV persistence. This process often leads to viral breakthrough in the 
E1/E2 regions and integration of viral DNA into the cell. The rupture releases the viral 
E6/E7 promoters and increases the expression of these transformer genes (Moody et al., 
2010; Ghittoni et al., 2010). Infection with a HR-HPV acts as a trigger for the cascade of 
events in which the mechanisms of repair or correction of cell replication, mediated by p53 
and retinoblastoma protein (Rb) are altered. Thus, the cell cycle is controlled by the virus, 
which triggers cellular changes that culminate in the transformation and immortalization of 
epithelial cells, thus establishing conditions for the start of cancer (Pim & Banks, 2010).  
Most HPV infections are transient and intermittent. Epidemiological studies have shown 
that HPV clearance in healthy, immune competent individuals, takes 8 to 12 months 
(Woodman et al., 2007). Cohort studies have shown that the continued presence of HR-HPV 
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is necessary for the development, maintenance and progression of HSIL (Ho et al., 1998; 
Bory et al., 2002; Muñoz et al., 2003; Dalstein et al., 2003; Cuschieri et al., 2005). To establish a 
persistent infection, HPVs gain access to mitotically active basal-layer keratinocytes, where 
low-copy replication begins. The viral DNA persists as a nuclear episome in infected cells. In 
the non-productive stage of infection, HPVs replicate at low copy number in mitotically active 
basal layer cells within stratified epithelia (Howley, 1996). HPV genomes can persist in 
proliferating keratinocytes for years or decades. This persistent phase of the viral lifecycle is 
characterized by detectable levels of viral genome, but the absence of virus production 
(Stubenrauch & Laimins, 1999), which is most likely a strategy to evade immune surveillance. 
So, there are two well-defined phenomena in the development of neoplasia - first,  there is an 
alteration in the cellular immune response that allows the persistence of the virus for many 
years (Walboomers et al., 1999; Nobbenhuis et al., 2001) and second, the phenomena of 
transformation in epithelial cells produced by oncogenic virus proteins (E6 and E7) through 
degradation of p53 and pRb (Scheffner et al., 1990; Boyer et al., 1996) and alteration in the 
expression of proto-oncogenes such as c-Myc and Ras (Marangoz et al., 1999).  
Genetic factors intrinsic to the host immune system play a role in susceptibility and/or 
resistance to the development of CC. Genetic factors associated with CC are polymorphisms 
in genes coding for tumor necrosis factor alpha (TNF-ǂ) (Wilson et al., 1997; Kirkpatrick et 
al., 2004), matrix metallopeptidase 1 (Lai et al., 2005), p53 (Dokianakis et al., 2000; Makni et 
al., 2000), Human Leukocyte Antigen-HLA (Apple et al., 1994; Hildesheim & Wand, 2002) 
and Fas (Lai et al., 2003). In a complete genome scan in families with more than one child 
with CC, it was found that in the long arm of chromosome 9 there is a susceptibility locus 
for the development of cervical carcinoma. In this locus, candidate genes could be 
potentially involved in genetic predisposition to this disease (Engelmark et al., 2006). Genes 
such as IKBKAP, PTPN3, TSCOT, AMBP, akna, TNFSF15, TNFSF8 and DEC1, have 
important roles in the development of the immune response.  
Among these is the akna gene, which is located in band 32 (9q32) on chromosome 9 (HGNC: 
24108) and consists of 24 exons (http://www.ncbi.nlm.nih.gov/gene/80709) (Figure 1A). 
Up to 9 different akna transcripts have been identified, resulting from alternative promoter 
usage, splicing and poly-adenylation. Of the 9 reported transcripts, the 3.1 kb F1 transcript 
has been functionally tested by our research group (Sims et al., 2005; Perales et al., 2010).  
The AKNA protein encoded by this gene is a nuclear protein consisting of 633 amino acids 
with an approximate weight of 63 kDa. AKNA contains an AT-hook motif of nine amino 
acids, RTRGRPADS (arginine, threonine, arginine, glycine, arginine, proline, alanine, 
aspartic acid, serine), which satisfies the consensus requirements of an AT hook DNA-
binding motif. The AT-hook is a small motif with a typical sequence signature, in which the 
tripeptide GRP (Gly58, Arg59 and Pro60) is the centre of the DNA-binding domain (Siddiqa et 
al; 2011). Besides, AKNA contains multiple PEST protein-cleavage motifs, which have been 
shown to target proteins of rapid turnover (Chevallier, 1993; Siddiqa et al., 2001) and has 
three domains located in the PEST regions: Leu10-Thr43, H149-Ser171, and P616-T63. These 
regions are sites of protein degradation so AKNA is considered to have a short half-life 
(Siddiqa et al., 2001) (Figure 1B). 
It has been demonstrated that AKNA expresses at least nine transcripts, some of which are 
expressed in a tissue-specific manner, reflecting its functional diversity. Besides, several of 
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these transcripts are predicted to encode proteins of 155, 137, 100 and 70 kDa. However, 
only two isoforms (70 and 100 kDa) are expressed in B- and T- cell lines, and both bind to 
the promoters of the costimulatory molecules of the immune response - CD40 and CD40L 
(CD40 ligand) (Sims et al; 2005). It has been shown that PEST-dependent cleavage of AKNA 
is key to its DNA binding function, because in the absence of the PEST-dependent cleavage, 
the expression of AKNA alone is not sufficient to induce CD40 expression (Sims et al., 2005; 
Ma et al., 2011). 
 
Fig. 1A. Akna gene localized in chromosome 9Q32 
 
Fig. 1B. Protein at-hook-containning transcription factor 
AT-hook proteins have been mainly recognized within the high mobility group A (HMGA) 
family, which includes chromatin remodeling proteins that coordinate transcriptional 
complexes to regulate gene expression (Cui & Leng, 2007). However, non-HMG AT-hook 
proteins have been identified and characterized. Among these, proteins with AT-hook-like 
motifs (ALMs) have been found to be capable of binding A/T-rich gene targets and 
regulating their transcription (Senthilkumar & Mishra, 2009; Gordon et al., 2010). In keeping 
with this notion, the human AKNA gene is a non-HMG transcription factor, which contains 
N- and C- terminus AT-hook motifs (Siddiqa et al., 2001; Sims et al., 2005). In addition, the 
AT-hook motif is considered to be the key to upregulation of expression of immune system 
co-activator molecules, since it has been shown to be directly involved in inducing the 
expression of molecules belonging to the TNFR family members. AKNA is mainly 
expressed in secondary lymphoid organs; it is expressed by germinal centre B lymphocytes 
during B-lymphocyte differentiation and by natural killer (NK) cells and dendritic cells 
(Siddiqa et al., 2001). AKNA binds the A/T-rich regulatory elements of the CD40 and 
CD40L promoters (a key receptor-ligand pair that is critical for antigen-dependent B cell 
development) and induces its expression (Siddiqa et al., 2001).  
Thus, in this chapter we will discuss the findings of our research group with respect to the 
immune response against HPV, CIN and CC, and associated genetic factors of susceptibility 
to the disease that we found in population studies, particularly the akna gene. 
2. Immune response against HPV & CIN 
In the HPV cycle in keratinocytes, mature virions are shed from the epithelial surface of 
infected keratinocytes. HPV infection is poorly immunogenic because it is productive 
(produces no characteristic local inflammation) and during infection there is little 
presentation of viral antigens to the immune system by professional antigen presenting 
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cells, both locally and systemically (Feller et al., 2010). There is no significant evidence in the 
literature of inflammation being a risk factor for lesion progression, as observed in several 
tumor models. On the contrary, the inflammatory infiltrate in patients with established 
lesions seems to display anti-inflammatory or suppressor characteristics, like the absence of 
inducible NO synthase (iNOS) expression by macrophages (Mazibrada et al., 2008) and 
indoleamina2’3’-deoxigenase expression by dendritic cells (Kobayashi et al., 2008). 
Interestingly, the number of infiltrating macrophages seems to increase in correlation with 
lesion grade (Hammes et al., 2007; Kobayashi et al., 2008; Mazibrada et al., 2008). T 
lymphocytes also infiltrate cervical HPV associated lesions, where the phenotype, 
abundance and balance between different populations are important in determining the fate 
of lesions or tumors (Piersma et al., 2004; van der Burg, 2007; Woo et al., 2008). Cellular 
immune response plays an important role in the control and course of HPV infection; this 
response varies depending on the degree of injury and the oncogenic potential of HPV. 
There is evidence that HPV interferes with cell cycle control, secondary to the accumulation 
of genetic abnormalities; this accounts for viral persistence and the progression of lesions. In 
many patients secondary factors, such as inadequate immune response, play an important 
role (Riethmuller & Seilles, 2000). 
At the cervical level, after infection of epithelial cells by HPV, a non-specific response is 
triggered accompanied by chemoattraction of neutrophils, activation of macrophages, 
activation of NK, natural antibodies and complement system; this is a first defensive barrier 
of specific immunity. Reticular cells of Langerhans (RCL) and some keratinocytes act as 
antigen presenting cells (APCs). RCLs are immature dendritic cells of myeloid origin 
residing in the squamous epithelium, including genital mucosa. RCL recognize the viral 
particles, capture antigens by micropinocytosis or mannose receptors, process captured 
proteins and transform them into immunogenic peptides, start the activation process (which 
includes a surface antigen polypeptide chain with HLA class II, CD40 and B7), migrate to 
local lymph nodes and present viral peptides to T cells in the context of the major 
histocompatibility complex (MHC) and costimulatory molecules (CD80, CD86 and CD40). 
Thus, native lymphocytes are activated and direct their differentiation into effector cells, 
initiating the antigen-specific immune response (Stern, 2008). 
During a primary immune response, depending on the microenvironment and the signals 
received from certain cytokines, naive CD4+ T cells can differentiate into three to four major 
subsets of Th cells, with distinct patterns  of cytokine secretion that drive different types of 
immune responses (Seder et al., 2003; Weaver et al., 2006). Briefly, IFN- and Interleukin 
(IL)-12  induce differentiation of Th1 cells to produce more IFN-, which enhances the 
clearance of viruses and the proliferation of specific CD8 cytotoxic T lymphocytes (CTL); on 
the contrary, if the local context does not express IL-12, it promotes the Th2 pathway which 
induces activation and expansion of B cells; these evolve, differentiating into plasma cells 
producing antibodies to viral proteins and inducing the expression of interleukins type IL-4, 
IL-5, IL-6 and IL-10 (Stern, 2008). The mediators of cell-mediated immunity against HPV 
infected cells and some tumors are CTL, which eliminate virally infected cells by means of 
antigen-specific, cell-mediated citotoxicity. Additionally, CD4+ T helper cells participate in 
the control of these processes.  Under certain conditions, the Tumor Growth Factor Beta 
(TGF-ǃ1) or IL-10 alone drives regulatory CD4+ T cell (Treg) differentiation which regulates 
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immune responses by several distinct mechanisms (Damoiseaux, 2006; Robertson & 
Hasenkrug, 2006). Thus, together with CTL, the only Th subset that is desirable in pre-
malignant CC lesions is that of Th1 cells, as IFN-Ǆ favors immune responses against viral 
infections.  
The natural history of these tumors is long and includes the following steps: infection, 
persistent infection, viral genome integration into the host cell genome, genomic alterations, 
immortalization and transformation of epithelial cells. During all these steps, evasion of the 
immune system is an obligatory feature. The immune evasion mechanisms displayed by the 
infected cells include absence of cell death (Tindle, 2002), blocking of type I Interferon 
signaling and reduction of antigen presentation by MHC-I (Ashrafi et al., 2005; Stern, 2008). 
2.1 Cellular immune response 
Local cellular immune response detected in SIL is characterized by a moderate infiltrate and 
a decreased inverted Th/Tc (CD4/CD8) ratio, with decreased proliferative capacity (Santin 
et al., 2001). An imbalance in the pattern of cytokines, as by an increase in type II interleukin 
(IL-4, IL-10, suppressing the cellular immune response) and a concomitant reduction in 
interleukin type I [(IL-2, gamma interferon (IFN-)], has been reported in women with SIL 
and CC (Giannini et al., 1998; Clerici et al., 1998; Bor-Ching et al., 2001).  Anti-tumor 
immunity in CC is activated by Th1 cytokines and inhibited by Th2 cytokines. Cytokines 
such as IL-4, IL-12, IL-10 and/or TGF-ǃ1, produced by various cell types (macrophages, 
dendritic cells and keratinocytes) have been involved in the suppression of cellular immune 
response (Giannini et al., 1998). 
The pattern of cytokines and their expression in women with CC biopsies has been 
analyzed. 80% of the tumors express low levels of mRNA of CD4 T lymphocytes and high 
levels of CD8 CTL. Most tumors express the mRNA of IL-4 and IL-10 and 100% of them 
express the mRNA of TGF-ǃ1 and IFN-. None of the tumors express the IL-12 mRNA, IL-6 
mRNA or TNF-ǂ (Alcocer et al., 2006). Immunohistochemical analysis of tumors has 
demonstrated the presence of IL-10 in tumor cells and cell koilocytes, but not in infiltrating 
lymphocytes, suggesting that the cells producing IL-10 can be transformed by HPV. On the 
other hand, a correlation has been found between the immunostaining of IL-10 protein, the 
level of mRNA IL-10 expression and the supernatants of HPV transformed cell lines 
expressing IL-10 and TGF-ǃ1 (Alcocer et al., 2006). These findings show a predominant 
expression of immunosuppressive cytokines, which help to downregulate tumor specific 
immune response in the tumor microenvironment (Alcocer et al., 2006). 
In a recent study, the functionality of peripheral blood T lymphocytes (PBL) and tumor-
infiltrating lymphocytes (TIL) of women with SIL and CC was assessed, including 
proliferation, mRNA expression of IL-2, IFN-Ǆ, IL-4, IL-10 and TGF-ǃ1, as well as the 
expression of CD3ζ. Using immunohistochemistry, we have seen that TIL is distributed in the 
stroma more than in epithelium in advanced stages of the disease where CD8 CTL prevail. 
PBL stimulated with phytohemagglutinin in patients with CC, proliferate less than in SIL 
patients and healthy subjects. Also, a significant difference is observed in the PBL stimulated 
with anti-CD3, between patients with CC and healthy subjects. This shows that women with 
CC have a poor proliferative PBL response and a lack of response to TIL (Díaz et al., 2009). 
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Antigen recognition of cells with cytotoxic capacity is mediated by receptors. In T cells, 
these are called T-cell receptors (TCR), which consist of a heterodimer of /chains and 
four chains, which together are recognized as TcR-CD3. These receptors are in turn 
associated with two "zeta" strings which are responsible for the transmission of activation 
signals within the cell. Zeta chains are also present in the receptor for NK cell antigens. 
Molecular studies have shown a decreased expression of the dimer formed by the zeta 
chain, in both T cells and NK cells, contributing to the inefficiency of the effector 
mechanisms of lymphocytic infiltrate present in the lesions. It has been demonstrated that 
there is a decreased expression of CD3-zeta chain in patients with CC and CIN (Kono et al., 
1996; Shondel et al., 2007), and that suppression in vivo can be the result of a circulating 
factor (Shondel et al., 2007). We found that IL-10 and TGF-ß1 produced by HPV-
transformed cells are responsible for CD3-zeta suppression in CC patients (Diaz et al., 2009). 
These processes are regulated by local factors derived from tumor cells.  
As there is an imbalance of cytokines in the microenvironment of these lesions, this affects 
the transcriptional level. Lymphocytic infiltrate present in the cervical lesions reflects an 
ineffective immune response (De-Gruijl et al., 1999). A significant correlation between low 
lymphocyte proliferation and decreased mRNA expression of CD3ζ has been reported in T 
lymphocytes stimulated with anti-CD3, indicating that T cell function decreases with the 
progression of CC (Díaz et al., 2009). These changes result in a loss of control of certain HPV 
16-18 genes and deregulation in the mechanisms of antigen presentation. Thus, the 
expression of HLA antigens is reduced or absent (Wang et al., 2002) and there is partial or 
total absence of Langerhans cells, considered to be they key antigen-presenting immune 
response against the tumor (Hachisuga et al., 2001). 
2.1.1 Role of AKNA in immune response 
Proteins containing AT hooks bind A/T-rich DNA through a nine amino-acid motif and are 
thought to co-regulate transcription by modifying the architecture of DNA, thereby 
enhancing the accessibility of promoters to transcription factors (Reeves & Nissen, 1990; 
Friedmann et al., 1993). AKNA is a human AT-hook protein that directly binds the A/T-rich 
regulatory elements of CD40 and CD40L promoters and coordinately regulates their 
expression. Consistent with its function, AKNA is a nuclear protein that contains multiple 
PEST protein-cleavage motifs, which are common in regulatory proteins with high turnover 
rates (Chevaillier, 1993).  
AKNA is mainly expressed by B and T lymphocytes, NK cells and dendritic cells. During B-
lymphocyte differentiation, AKNA is mainly expressed by germinal centre B lymphocytes, a 
stage in which receptor and ligand interactions are crucial for B-lymphocyte maturation 
(Berek et al., 1991; Liu et al., 1991; Jacob & Kelsoe, 1992; McHeyzer-Williams et al., 1993; 
Clark & Ledbetter, 1994; MacLennan, 1994; Arpin et al., 1995; Liu et al., 1996). These findings 
show that an AT-hook molecule can coordinately regulate the expression of a key receptor 
and its ligand, and point towards a molecular mechanism that explains homotypic cell 
interactions (Siddiga et al., 2001).  
Human AKNA is a transcription factor with N- and C- terminus AT-hook motifs (Siddiga 
et al., 2001; Sims et al., 2005). Thus, it is possible that AKNA expression plays a role in 
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mechanisms that, if altered, could result in systemic and potentially fatal disorders. 
Human AKNA is encoded by a single gene located within the FRA9E region of 
chromosome 9q32 (Sims et al., 2005), a common fragile site (CFS) linked to loss-of-
function mutations that often lead to inflammatory and neoplastic diseases (Thye et al., 
2003; Landvik et al., 2009; Savas et al., 2009). Based on this reasoning, two independent 
gene-targeting mouse models were engineered to assess in vivo the physiological 
significance of akna gene expression. It was found that the phenotypes resulting from the 
deletion of the putative C-terminus ALM sequence (AKNA KO) or disruption of AKNA’s 
exon 3 (AKNA KO2) were by and large similar: a) mice died prematurely at neonatal age; 
b) probable causes of sudden death included acute inflammatory reactions and alveolar 
destruction; c) triggering of the observed inflammation appeared to be pathogen-induced; 
d) systemic neutrophil mobilization and alveolar infiltration were routinely observed and; 
e) concerted activation of neutrophil-specific chemokine, cytokine and proteolytic enzyme 
expression seemed to be the norm. The central goal of the AKNA function was provided 
and supports the hypothesis that AKNA expression plays an important role in the 
mechanisms that regulate the magnitude of inflammatory responses to pathogens (Ma et 
al., 2011). 
It was reported that deletion of murine akna gene results in small, frail mice that die 
suddenly at 10 days of life. Besides, AKNA KO mice present systemic inflammation, 
predominantly in the lungs, that is accompanied by enhanced leukocyte infiltration 
(mainly neutrophils) and alveolar destruction. Because AKNA functions as an AT-hook 
transcription factor, Ma and colleagues investigated expression of genes related to 
neutrophil function and found a significant enrichment in genes encoding inflammatory 
cytokines (IL-1, IFN-), inflammatory proteins [neutrophilic granule protein (NGP), 
cathelin-related antimicrobial peptide (CRAMP), S100A8/9] and proteases (matrix 
metalloprotease-9; MMP-9), which are implicated in alveolar damage. Given that AKNA 
deficiency results in an increase of MMP-9, IL-1, IFN-, NGP, and CRAMP S100A9 gene 
expression, it is possible that AKNA functions as a multi-faceted transcriptional repressor 
that can coordinately temper pathway-specific gene transcription (Ma et al., 2011; 
Moliterno & Resar, 2011).  
It has been suggested that AKNA´s function is necessary to regulate the magnitude of 
pathogen-elicited neutrophil activation, proliferation and tissue infiltration by coordinately 
restricting autocrine/paracrine cytokine and chemokine. This implies that when AKNA is 
productively expressed, neutrophil reactions are increased to neutralize and destroy 
pathogens. However, loss of AKNA expression could exacerbate neutrophil activation and 
cause irreparable tissue damage. This hypothesis is in tune with the enhanced MMP-9, IL-
1, IFN-, and NGP expression and the resulting lethal syndrome associated with AKNA 
deficiency, in which transcriptional repression is seemingly lost (Ma et al., 2011). It is 
interesting to note that a significantly decreased expression of AKNA in CD4+ T cells has 
been reported in active patients with Vogt-Koyanagi-Harada Syndrome (VKH, a systemic 
autoimmune disease). It is unknown whether a decreased AKNA could play a role in VKH 
syndrome via downregulation of CD40 and CD40L (Mao et al., 2011). In conclusion, it will 
be interesting to determine if loss-of-function mutations, polymorphisms or epigenetic 
alterations in akna contribute to myeloid function, inflammation and neoplastic 
transformation. 
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2.1.2 Evasion of immune surveillance 
There is evidence of CIN regression to normal epithelium and it has been suggested that 
cellular immune response is responsible for HPV clearance (Woo et al., 2010). The cellular 
immune response mechanisms against HPV are similar to other responses used against viral 
infection. However, sometimes these mechanisms fail; allow HPV persistence and tumor 
development. There are several mechanisms for immune response evasion; however, three 
operate in HPV-infected women: 1) the expression of immunesuppressor cytokines such as, 
IL-10 and TGF-ǃ1; 2) Fas ligand expression in HPV-transformed cells, and 3) the presence of 
Treg cells (de Gruijl et al., 1999; Bor-Ching et al., 2001; Alcocer et al., 2006) which are 
associated with HPV persistence (Molling et al., 2007) and CIN development (Scott et al., 
2009). The presence of immune suppressor cytokines in HPV-CIN patient sera has been 
demonstrated (Clerici et al., 1997). 
It is well known that IL-10 and TGF-ǃ1 expression are initiated at the onset of HPV infection 
and increase as the disease progresses.  This allows us to postulate IL-10 as an HPV escape 
mechanism of the cellular immune response (Bermúdez-Morales et al., 2008). IL-10 and TGF-
ǃ1 are expressed in HPV-transformed cells and are induced by HPV E2, E6 and E7 proteins 
(Bor-Ching et al., 2001; Peralta et al., 2006; Bermúdez et al., 2011).  
A susceptibility factor for the development of CC is an alteration of the immune response in 
patients. This immunosuppression produces a decrease of CTL and NK activation, cells that 
play an important role in tumor cell elimination. Consequently, HPV-transformed cells do 
not express antigen presenting molecules, HLA class I and II, an effect mediated by IL-10 
and TGF-ǃ1 and by the presence of Treg (Keating et al., 1995; Ploegh, 1998; Nakamura et al., 
2007). IL-10 and TGF-ǃ1 also decrease CD3ζ chain expression of the T-cell antigen receptor 
(Díaz et al., 2009; Patel & Chiplunkar, 2009), which is responsible for antigen recognition. 
Additionally, it is well known that there are infiltrating T-lymphocytes in CIN and CC, 
predominantly CD8 CTL; however, these lymphocytes have a low proliferation rate and the 
absence of costimulatory molecules of cellular immune response. Thus, there is no activation 
of CTL and no elimination of neoplastic cells (Alcocer et al., 2006; Díaz et al., 2009). 
2.2 Humoral immune response 
Regarding the humoral response, variability has been reported in antibody titers, regardless 
of the high levels of circulating immune complexes, especially in those patients with tumors 
in advanced stages. In early lesions, high levels of IgG antibodies against HPV oncogenic 
proteins E6/E7 and E4 have been observed, as a result of greater antigenic stimulation, with 
a decreased IgG1/IgG2 ratio; this is a reflection of the Th1/Th2 imbalance (Matsumoto et 
al., 1999; Pedroza-Saavedra et al., 2000). In advanced tumors, higher titers of IgA and IgM 
decrease proportionally as the disease progresses, perhaps due to an impaired immune 
system (Baay et al., 1997). 
3. Genetic susceptibility and AKNA polymorphisms 
3.1 Cancer genetic susceptibility 
Scientific advances have enabled us to predict susceptibility to developing diverse diseases, 
including breast, ovarian, and other cancers like CC. With this new knowledge we are able 
to identify, in a specific population, who are at greater risk of developing a disease. 
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Cancer is a complex disease that should be considered as a genetic disease. In this respect, 
genetic factors are not considered to be a direct cause of disease but, in combination with 
environmental factors, have effects on the resistance or susceptibility to diseases as cancer. 
Furthermore, cancer risk assessment includes the collection and interpretation of multiple 
factors that contribute to carcinogenesis. These factors include personal and family health 
history, reproductive history and hormone use, environmental risk factors such as HPV 
infection and lifestyle habits associated with cancer risk, as well as any genetic/genomic 
information (Jenkins, 2009) (Figure 2). 
 
Fig. 2. Factors affecting the persistence of HPV infection and cervical cancer onset 
A number of mechanisms leading to cancer have been identified through the discovery of 
structural alterations of genes called oncogenes and tumour suppressor genes. Somatic and 
germinal mutations are rare but play a determinant role in the emergence of cancer, while 
common and frequent variations (polymorphisms) play a role in cancer susceptibility and in 
the effects of anticancer drugs (efficacy and toxicity)(Robert, 2010; Hildesheim & Wand, 2002). 
The susceptibility of a woman to developing CC is largely attributed to the type of HPV 
infecting the cervix and the persistent HPV infections associated with a high viral load; these 
are considered to be the major risk factors for persistent cervical lesions (Schlecht et al., 2003; 
de Araujo Souza & Villa, 2003). Persistence of infections by HR-HPV types is the single 
greatest risk factor for malignant progression. Although prophylactic vaccines have been 
developed that target HR-HPV types, there is a continuing need to better understand the 
virus–host interactions that underlie persistent benign infection and progression to cancer 
(Bodily & Laimins, 2011). Even though HPV is considered to be a necessary but not 
sufficient cause for CC, the hereditary component has been reported and several studies 
indicate that genetic background of the host is important for CC susceptibility and for the 
carcinogenic process. (de Araujo Souza & Villa, 2003; Hemminki et al., 1999; Magnusson et 
al., 2000; Wank & Thomssen, 1991).  
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To study the genetic background and to explore the differences in individual cancer 
susceptibility, a recent focus of research efforts has been on SNPs (single nucleotide 
polymorphisms). SNPs are the most common known form of human genetic variation and 
are defined as stable single-base substitutions with a frequency of greater than 1% in at least 
one population (Taylor et al., 2001; Meyer et al., 2008). For cancer research, the focus has 
been on SNPs that alter the function or expression of a gene, to attempt to explain observed 
associations with a pathogenic mechanism. Indeed, genetic polymorphisms in functionally 
critical genes such as immune response genes have been suggested as risk factors for the 
development of a variety of cancers including CC (Taylor et al., 2001; Milam et al., 2007). 
There are several reports about genes related to immune response (e.g. MHC genes), 
cytokine genes, genes involved with cancer development (e.g. p53) and CC susceptibility 
(Glew et al., 1992; Haukin et al., 2002; Sierra-Torres et al., 2003).  
Concerning HLA polymorphisms and the risk of CC, discordant results have often been 
observed among different populations, where the most consistent reports are for the 
DRB1*13 and DRB1*0603 alleles as a protection factor with  OR  0.3-0.4 (Hildesheim & 
Wand, 2002; Apple et al., 1994; Maciag et al., 2002) and increasing risk for the DQB1*03 and 
DRB1∗1501-DQB1∗0602 with OR 2.9 and for the DRB1∗0301-DQB1∗0201 haplotype, which 
was associated with a two-fold reduction in risk for transient and persistent HPV infections. 
DRB1∗1102-DQB1∗0301 showed a lower risk effect only for persistence. DRB1∗1602-
DQB1∗0502 and DRB1∗0807-DQB1∗0402 were associated with seven- and three-fold 
increases in risk for persistence, respectively (Hildesheim & Wand, 2002; Apple et al., 1994; 
Maciag et al., 2002). More recently, a study of CC cases that were HPV-16 positive and 
controls, carried out in Mexican population, showed consistent results of association 
between the HLA-DRB1*15 (OR, 3.9; 95 % CI, 1.6-10.2) and the DRB1*15 DQB1*0602 
haplotype (OR, 4.1; 95 % CI, 1.4-12.7) in CC cases, compared with the control group. Also for 
the HLA class I, the haplotypes HLA-A2-B44-DR4-DQ*0302, HLA-A24-B35-DR16-DQ*0301 
and HLA-A2-B40-DR4-DQ*0302 showed a positive association with CC (OR> 1), while 
HLA-A2-B39-DR4-DQ*0302, HLA-A24-B35-DR4-DQ*0302 and HLA-A68-B40-DR4-DQ*0302 
showed a negative association (OR <1) (Hernández et al., 2009). 
Also TNF-ǂ has been implicated in direct and indirect control of HPV infection through 
induction of apoptosis and stimulation of inflammatory responses. Two types of 
polymorphism have been described in TNF-ǂ gene. One involves several polymorphisms in 
the TNF-ǂ promoter region, including SNPs at positions -76, -161, -237, -243, -308 (G→A), -
375, -568, -572, -575, -857 and -863; the second involves SNPs in DNA microsatellites (Martin 
et al., 2006). Evidence suggests that the GG genotype of SNP G/T at position -308 in the 
TNF-ǂ promoter region, has been associated with CC precursor lesions (Kirkpatrick et al., 
2004). Other TNF-ǂ SNPs with reported associations with CC include -237, -572, -857 and –
863, and haplotype analysis has again strengthened these regions as potential targets for 
determination of CC susceptibility. The other TNF-ǂ polymorphisms associated with CC are 
the microsatellite polymorphisms TNF-ǂ2, TNF-ǂ8 and TNF-ǂ11, with significant 
associations between CIN I and the TNF-ǂ8 allele, CIN III and the TNF-ǂ2 allele in patients 
who are HPV-18 positive, and TNF-ǂ11 with HPV-16 infection and CIN, in combination 
with HLA DQB allele (Martin et al., 2006).  
Also, p53 polymorphism in codon 72 has been associated with CC. It has been observed that 
the p53 variants differ biochemically from each other and that the p53-Arg is more 
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susceptible to HPV E6-mediated degradation than the proline variant (Madeleine et al, 2002; 
Beckman et al., 1994). Furthermore, Storey et al., have shown that individuals who were 
homozygous for the arginine allele had a seven times higher persistence of HPV associated 
to CC than heterozygous proline/arginine women (Storey et al., 1998). However, similar 
analyses performed in other populations did not confirm the association between such 
polymorphism of the p53 gene and the risk of developing HPV-associated lesions 
(Minaguchi et al., 1998; Hildesheim et al., 1998). Beside MHC and p53 polymorphism, 
polymorphisms in cytokine genes can influence immune responses to HPV infection, 
possibly modifying risks of CC. (Kirkpatrick et al., 2004; Howell & Rose, 2006; Bidwell et al., 
1999; Haukin et al., 2002; Stanczuk et al., 2002; Matsumoto et al., 2010).   
IL-10 and TGF-ǃ1 polymorphisms have also been reported in diverse populations. G allele 
of SNP (A/G) at position -1082 in interleukin-10 promoter region, has been associated with 
high levels of IL-10, which increases with disease severity (p<0.001) (Farzaneh et al., 2006; 
Singh et al., 2009; Matsumoto et al., 2010). On the other hand, CC patients with -509TT 
showed marginal low risk for stage I cancer (p = 0.04, OR = 0.95, 95% CI = 0.91-0.99) but -
509TT genotype of TGF-ǃ1 was associated with increased risk for stage II cancer (p = 0.07, 
OR = 3.13, 95% CI = 0.87-11.14) (Singh et al., 2009). 
3.2 AKNA polymorphism  
A number of genetic susceptibility factors have been proposed, but with the exception of the 
HLA class II, have not shown consistent results among studies. The first genome-wide 
linkage scan was performed using 278 affected sib-pairs to identify loci involved in 
susceptibility to CC. This study found that 9q32 contains the susceptibility locus for CC, and 
some of these candidate genes are potentially involved in the genetic predisposition to this 
disease; among these genes is akna (Engelmark et al., 2006).  
AKNA is a transcriptional factor that is involved in lymphocyte maturation and in the up-
regulation of signaling molecules, such as CD40L (Siddiqa et al., 2001; Sims et al., 2005). 
Even though the precise molecular mechanisms for AKNA function have not been 
defined, AT-hook transcription factors have emerged as multifaceted regulators that can 
activate or repress broad A/T-rich gene networks. Thus, alterations of AT-hook genes 
could affect the transcription of multiple genes causing global cell dysfunction which 
could mediate DNA bending and chromatin rearrangement (Cairns et al., 1999; Ma et al., 
2011).  
Although functional data concerning AKNA are scarce, sequences of akna genes deposited 
in the GenBank databases are increasing. SNP analysis in the Genecard site 
(http://www.genecards.org/), at the 313 SNPs, reported that, for all akna genes, only 11 of 
them are coding non- synonyms. Among all the SNPs reported for akna, SNP (rs3748178) 
involving the transition G/A, at nucleotide 114189600(-) of chromosome 9 (accession no. 
AK024431) (Ota et al., 2004), appears to be functionally relevant. This mutation produces an 
R to Q amino acid change at codon 1119 (protein accession NP_110394). Such R/Q mutation 
occurs at an important AT-hook DNA binding motif within the highly conserved core that 
has a typical sequence pattern centered around a glycine-arginine-proline (GRP) tripeptide 
(codons 1118-1120). This short conserved sequence is relevant because it is necessary to bind 
DNA (Aravind & Landsman, 1998). The importance of producing a GQP core motif, instead 
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of a GRP, is because glutamine lacks the positive charge that arginine has and thus 
potentially affects its DNA-binding capacity (Reeves & Nissen, 1990; Huth et al., 1997).  
The AT-hook motif interacts directly with the minor groove of DNA in AT rich regions. 
Although some sequence specificity is present in the AT hook itself, and this may affect the 
main function of this motif (which is to anchor to the proteins in the minor groove of the 
DNA, near sequences targeted by other regions of the AT hook proteins), it is probably 
dependent on the spacing between successively interacting AT-hooks and their binding sites 
may be crucial for conformational changes of the DNA (Huth et al., 1997; Aravind & 
Landsman, 1998). A SNP at codon 1119 of the akna gene, yields a potentially relevant amino 
acid change (R1119Q) located at the DNA binding AT-hook motif; the AT hook may serve as 
a contact which affects the specificity and affinity of the DNA binding protein (Figure 3). 
  
Fig. 3. AT-hook akna polymorphism (rs3748178) 
Recently, we examined the frequency of Arginine (R) or Glutamine (Q) 1119 alleles of the 
akna gene in 47 HPV-positive biopsies from Mexican women with cervical lesions, with 
diagnoses of 21 CIN and 26 CC, as well as in 50 healthy controls without cervical lesions and 
with HPV-negative status (194 alleles in total). Genomic DNA was amplified by PCR and 
examined by restriction fragment length polymorphism (RFLP) analysis (Perales et al., 
2010). We observed that the frequencies of genotypes in all studied 97 allele pairs were: 
R/R= 0.597, R/Q= 0.278, Q/Q= 0.123 and the individual frequencies of the R and Q alleles 
were 0.737 and 0.262, respectively. Q/Q homozygozity was present in 8.33% of healthy 
controls, 16.67% of CIN and 75% of CC patients. The distribution of the different genotypes 
in the three study groups showed a statistically significant difference by Fisher’s exact test 
(Perales et al., 2010) (Figure 4). 
This study, using a bivariate analysis with a model of multinomial logistic regression, with 
respective confidence intervals of 95% (IC 95%), showed that these differences were highly 
significant for the presence of Q/Q in CC (p= 0.01, OR= 3.66, 95%CI: 1.35- 9.94); there was a 
strong association between the homozygote phenotype Q/Q and the severity of the cervical 
lesions (Perales et al., 2010). These data support the importance of the genomic region where 
akna is located (Table 1). 
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akna genotype distribution, Modified from Perales G, et al,. Biomarkers, 2010 
Fig. 4. akna genotype distribution  
 
CI, confidence interval; CIN, cervical intraepithelial neoplasia; Multinomial logistic regression: ORc, 
unadjusted odds ratio; ORa, adjusted OR by age. Modified from Perales G, et al,. Biomarkers, 2010 
Table 1. Risk of Cervical cancer associated with Q/Q akna genotype 
The AT-hook akna motif studied in this work is present in all reported akna isoforms except 
in the C1 and C2 isoforms (Sims et al., 2005). Therefore, the relevance of our observation is 
valid for the wide range of isoforms potentially expressed by the akna gene (Sims et al., 
2005). The observed frequencies of akna Q/Q genotype in this group of 194 studied 
chromosomes, and the demonstration of a statistically significant association between a 
mutation in the akna gene (that results in an R-Q amino acid change) and susceptibility to 
CC, is of high relevance to biological knowledge of the development of CC. Whether this 
mutation contributes to an alteration of AKNA protein structure and immune function, and 
to CC development, is under investigation (Perales et al., 2010). 
4. Conclusions and perspectives 
HPV infection has two different cycles, the productive cycle and the transforming cycle. In 
the productive cycle of HPV, which occurs in keratinocytes, mature virions are shed from 
the epithelial surface of infected keratinocytes. HPV infection is poorly immunogenic 
because it is productive (produces no characteristic local inflammation) and during infection 
there is little presentation of viral antigens to the immune system by professional antigen-
presenting cells, both locally and systemically. In some cases, HPV infection produces a non-
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inflammatory reaction. There is no adequate cellular immune response, due to excessive 
secretion of immunosuppressor cytokines, essentially IL-10, which produces a reduction of 
antigen-presenting and co-stimulatory molecules, and hence no recognition by the 
surrounding CD8 CTL. The AKNA transcription factor that induces the expression of 
stimulatory molecules, such as CD40 and CD40L, may play an important role in regulating 
the immune response against HPV. We found a genetic variant of the akna gene that has 
high frequency in patients with CC. Consequently, we believe that this genetic variant plays 
an important role, as a risk factor in CC development; the absence of AKNA protein may 
play an important role in the immune response against HPV. Thus, at the cervical level, after 
infection of epithelial cells by HPV, a nonspecific response is triggered that is accompanied 
by chemoattraction of neutrophils. Therefore, this interesting information about akna-KO 
raises important questions and further avenues for biomedical research. For instance, the 
enrichment of AKNA in wild-type neutrophils, and excess neutrophil counts in the absence 
of AKNA, suggests that this protein is important in the negative regulation of myeloid 
differentiation or neutrophil survival. It is of high relevance to determine whether loss-of-
function mutations, polymorphisms or epigenetic alterations in akna contribute to myeloid 
diseases, such as myeloproliferative neoplasias, and CC. In conclusion, AKNA appears to be 
an important genetic factor associated with the progression of CC and genes regulated by 
this transcription factor could be involved in the resistance to CC progression. 
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